Fast Neutrons Help Produce Medical Isotopes
By MedImaging International staff writers Posted on 21 Jun 2015 |
Image: Chemist Amanda Youker purifying molybdenum-99 (Photo courtesy of Wes Agresta/ ANL).
An innovative process is being used to create a stable commercial source of molybdenum radioisotopes, widely used in diagnostic imaging.
Developed by researchers at Argonne National Laboratory (ANL; Lemont, IL, USA), in cooperation with SHINE Medical Technologies (Monona, WI, USA) the process uses fast neutrons to bombard an aqueous solution of low enriched uranium (LEU), creating fission products that include molybdenum-99 (Mo-99), the parent isotope of technetium-99m (Tc-99m), a radioactive tracer element used in more than 40 million medical diagnostic procedures each year in the United States alone.
The isotope is created when Mo-99 spontaneously decays through the release of a beta particle from its nucleus. Because of its unstable nature, Mo-99 does not occur naturally and is traditionally produced using highly enriched uranium (HEU) in nuclear reactors. Mo-99 is also not produced in the United States, leaving the country to rely on isotope supply from international sources, including a Canadian research reactor that will cease regular production next year, which will reduce the global supply.
The SHINE process is easier to implement, since it involves the bombardment of a LEU uranyl sulfate solution with fast neutrons generated on-site in the ANL linear accelerator. The LEU breaks down after bombardment into hundreds of different isotopes, including Mo-99, which is the result of six percent of the fissions created during the process. The Mo-99 must then be separated from the other fission products before it can be transported for use.
“The development of techniques for domestic production of Mo-99 is a critical national priority and one fully supported by our work at Argonne,” said George Vandegrift, PhD, an ANL distinguished fellow who leads the Mo-99 development efforts. “Millions of patients each year rely on Mo-99 for life-saving diagnostic procedures, but the stability and safety of that supply is threatened by a variety of factors.”
Tc-99m is used in about 85% of all medical imaging procedures worldwide. It is currently made in reactors in Canada, the Netherlands, Belgium, France, Australia, and South Africa.
Related Links:
Argonne National Laboratory
SHINE Medical Technologies
Developed by researchers at Argonne National Laboratory (ANL; Lemont, IL, USA), in cooperation with SHINE Medical Technologies (Monona, WI, USA) the process uses fast neutrons to bombard an aqueous solution of low enriched uranium (LEU), creating fission products that include molybdenum-99 (Mo-99), the parent isotope of technetium-99m (Tc-99m), a radioactive tracer element used in more than 40 million medical diagnostic procedures each year in the United States alone.
The isotope is created when Mo-99 spontaneously decays through the release of a beta particle from its nucleus. Because of its unstable nature, Mo-99 does not occur naturally and is traditionally produced using highly enriched uranium (HEU) in nuclear reactors. Mo-99 is also not produced in the United States, leaving the country to rely on isotope supply from international sources, including a Canadian research reactor that will cease regular production next year, which will reduce the global supply.
The SHINE process is easier to implement, since it involves the bombardment of a LEU uranyl sulfate solution with fast neutrons generated on-site in the ANL linear accelerator. The LEU breaks down after bombardment into hundreds of different isotopes, including Mo-99, which is the result of six percent of the fissions created during the process. The Mo-99 must then be separated from the other fission products before it can be transported for use.
“The development of techniques for domestic production of Mo-99 is a critical national priority and one fully supported by our work at Argonne,” said George Vandegrift, PhD, an ANL distinguished fellow who leads the Mo-99 development efforts. “Millions of patients each year rely on Mo-99 for life-saving diagnostic procedures, but the stability and safety of that supply is threatened by a variety of factors.”
Tc-99m is used in about 85% of all medical imaging procedures worldwide. It is currently made in reactors in Canada, the Netherlands, Belgium, France, Australia, and South Africa.
Related Links:
Argonne National Laboratory
SHINE Medical Technologies
Latest Nuclear Medicine News
- New PET Agent Rapidly and Accurately Visualizes Lesions in Clear Cell Renal Cell Carcinoma Patients
- New Imaging Technique Monitors Inflammation Disorders without Radiation Exposure
- New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access
- New Radiotheranostic System Detects and Treats Ovarian Cancer Noninvasively
- AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging
- Early 30-Minute Dynamic FDG-PET Acquisition Could Halve Lung Scan Times
- New Method for Triggering and Imaging Seizures to Help Guide Epilepsy Surgery
- Radioguided Surgery Accurately Detects and Removes Metastatic Lymph Nodes in Prostate Cancer Patients
- New PET Tracer Detects Inflammatory Arthritis Before Symptoms Appear
- Novel PET Tracer Enhances Lesion Detection in Medullary Thyroid Cancer
- Targeted Therapy Delivers Radiation Directly To Cells in Hard-To-Treat Cancers
- New PET Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Algorithm Predicts Prostate Cancer Recurrence in Patients Treated by Radiation Therapy
- Novel PET Imaging Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Ultrafast Laser Technology to Improve Cancer Treatment
- Low-Dose Radiation Therapy Demonstrates Potential for Treatment of Heart Failure